Shenyang Xingqi Pharmaceutical Co., Ltd. Class A

Shenyang Xingqi Pharmaceutical Co., Ltd. Class A

SSZSE:300573
34.04
CNY
+0.80
(+2.41%)
2.24EPS
16.19P/E
12.93BMarket Cap
Apr 22Next Earn

Total Valuation

CNY

As of September 30, 2026, Shenyang Xingqi Pharmaceutical Co., Ltd. Class A carries a market capitalization of 12.93B, placing it among publicly traded companies globally. Its enterprise value stands at 12.50B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap12.93B
Enterprise Value12.50B

Important Dates

Shenyang Xingqi Pharmaceutical Co., Ltd. Class A's next confirmed earnings release is scheduled for April 22, 2027.

Earnings Date4/22/2027

Share Statistics

As of September 30, 2026, Shenyang Xingqi Pharmaceutical Co., Ltd. Class A has 354.92M shares outstanding.

Shares Outstanding354.92M

Valuation Ratios

As of September 30, 2026, Shenyang Xingqi Pharmaceutical Co., Ltd. Class A trades at a trailing price-to-earnings ratio of 16.19. The price-to-sales ratio is 4.63, and the price-to-book ratio stands at 5.79.

PE Ratio16.19
PS Ratio4.63
PB Ratio5.79
P/TBV Ratio6.39

Enterprise Valuation

As of September 30, 2026, Shenyang Xingqi Pharmaceutical Co., Ltd. Class A trades at an EV/EBITDA multiple of 13.12 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 4.45 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 13.12 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 12.50B versus a market cap of 12.93B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales4.45
EV / EBITDA13.12
EV / EBIT13.12

Financial Position

As of September 30, 2026, Shenyang Xingqi Pharmaceutical Co., Ltd. Class A maintains a current ratio of 1.89, meaning it holds 1.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 4.73, indicating elevated leverage, while an interest coverage ratio of 543.03 demonstrates strong ability to service its debt obligations.

Current Ratio1.89
Quick Ratio0.89
Debt / Equity4.73
Debt / EBITDA0.11
Interest Coverage543.03

Financial Efficiency

CNY

These figures cover the twelve months ended September 30, 2026. The company generates approximately 1.17M in revenue per employee across its workforce of 2,396.00, a quick read on workforce productivity versus industry peers.

Revenue Per Employee1.17M
Employee Count2,396.00

Taxes

CNY

Over the twelve months ended September 30, 2026, Shenyang Xingqi Pharmaceutical Co., Ltd. Class A recorded 116.50M in income tax expense. That works out to an effective tax rate of 12.68, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 918.55M, leaving 802.06M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax116.50M
Effective Tax Rate12.68

Stock Price Statistics

CNY

As of the close on November 17, 2026, Shenyang Xingqi Pharmaceutical Co., Ltd. Class A's stock has declined approximately 31.55% over the past 52 weeks. The 50-day moving average sits at 35.35, while the 200-day moving average is 42.02.

52-Week Price Change-31.55%
50-Day Moving Average35.35
200-Day Moving Average42.02

Income Statement

CNY

Over the twelve months ended September 30, 2026, Shenyang Xingqi Pharmaceutical Co., Ltd. Class A generated 2.81B in revenue and converted that into 802.06M in net income, yielding earnings per share of 2.24. EBITDA reached 952.56M, while operating income came in at 956.39M.

Revenue2.81B
Gross Profit2.31B
Operating Income956.39M
Pretax Income918.55M
Net Income802.06M
EBITDA952.56M
EBIT952.56M
Earnings Per Share (EPS)2.24

Balance Sheet

CNY

As of September 30, 2026, Shenyang Xingqi Pharmaceutical Co., Ltd. Class A holds 537.82M in cash and equivalents against 105.58M in total debt, resulting in a net debt position of -449.82M. Total book value stands at 2.23B, with working capital of 536.74M providing operational flexibility.

Cash & Cash Equivalents537.82M
Total Debt105.58M
Net Debt-449.82M
Equity (Book Value)2.23B
Book Value Per Share6.29
Working Capital536.74M

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-277.50M

Margins

Over the twelve months ended September 30, 2026, Shenyang Xingqi Pharmaceutical Co., Ltd. Class A posted a gross margin of 82.28, reflecting its pricing power and cost economics. The operating margin of 34.07 and net profit margin of 28.58 provide insight into operational efficiency.

Gross Margin82.28
Operating Margin34.07
Pretax Margin32.73
Profit Margin28.58
EBITDA Margin33.94

Dividends & Yields

CNY

Over the twelve months ended September 30, 2026, Shenyang Xingqi Pharmaceutical Co., Ltd. Class A paid dividends of 0.99 per share. The dividend payout ratio of 44.14 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 3.55, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Shenyang Xingqi Pharmaceutical Co., Ltd. Class A shareholders.

Dividend Per Share0.99
Payout Ratio44.14
Shareholder Yield3.55

Stock Splits

Shenyang Xingqi Pharmaceutical Co., Ltd. Class A's most recent stock split took place on May 22, 2026 with a 20:29 split ratio.

Last Split Date5/22/2026
Split Ratio20:29

Scores

As of September 30, 2026, Shenyang Xingqi Pharmaceutical Co., Ltd. Class A has an Altman Z-Score of 13.08, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score13.08